MEFV and myeloid sarcoma: Four of 151 patients carried a double mutation (1 patient w/o MS: NLRP3 and TNFRSF1A variants, 3 patients with MS: two with MEFV and TNFRSF1A variants, one with MEFV and NLRP3 variants) leading to 155 AID in total (AID w/o MS = 44; AID with MS = 111) (Table 1).